Involved Node Radiation Therapy: An Effective Alternative in Early-Stage Hodgkin Lymphoma
Menée sur une cohorte de 97 patients atteints d'un lymphome hodgkinien de stade I-II (durée de suivi après le traitement : 5 ans), cette étude rétrospective évalue, du point de vue du contrôle de la maladie, de la survie globale à 4 ans et des événements indésirables, l'efficacité et la toxicité d'un protocole thérapeutique comportant une radiothérapie des ganglions lymphatiques impliqués, puis une chimiothérapie ABVD
The involved node radiation therapy (INRT) strategy was introduced for patients with Hodgkin lymphoma (HL) to reduce the risk of late effects. With INRT, only the originally involved lymph nodes are irradiated. We present treatment outcome in a retrospective analysis using this strategy in a cohort of 97 clinical stage I-II HL patients. Patients were staged with positron emission tomography/computed tomography scans, treated with adriamycin, bleomycin, vinblastine, and dacarbazine chemotherapy, and given INRT (prechemotherapy involved nodes to 30 Gy, residual masses to 36 Gy). Patients attended regular follow-up visits until 5 years after therapy. The 4-year freedom from disease progression was 96.4% (95% confidence interval: 92.4%-100.4%), median follow-up of 50 months (range: 4-71 months). Three relapses occurred: 2 within the previous radiation field, and 1 in a previously uninvolved region. The 4-year overall survival was 94% (95% confidence interval: 88.8%-99.1%), median follow-up of 58 months (range: 4-91 months). Early radiation therapy toxicity was limited to grade 1 (23.4%) and grade 2 (13.8%). During follow-up, 8 patients died, none from HL, 7 malignancies were diagnosed, and 5 patients developed heart disease. INRT offers excellent tumor control and represents an effective alternative to more extended radiation therapy in the combined modality treatment for early-stage HL.
International Journal of Radiation Oncology, Biology, Physics